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PublishedSCRS an
by ElsevPURPOSE: To evaluate the effect of a1-adrenergic receptor antagonists (a1-ARAs) on pupil
diameter and determine whether the diameter predicts intraoperative floppy-iris syndrome (IFIS).
SETTING: Ophthalmology Section, Palermo University, Palermo, Italy.
DESIGN: Prospective cohort study.
METHODS: Male outpatients taking tamsulosin, a1-ARAs, or no a1-ARAs having phacoemulsifica-
tion were recruited. Pupils were measured 1 month preoperatively, immediately preoperatively, and
postoperatively under mesopic low (0.4 lux) and high (4.0 lux) illumination after pharmacologic
dilation. The IFIS severity was graded.
RESULTS: Each group comprised 50 patients. Pharmacologic dilation in both a1-ARA groups was
statistically significantly less than in the no a1-ARA group 1 month preoperatively, immediately
before surgery, and postoperatively (PZ.001, P<.0005, and P<.0005, respectively). The IFIS
incidence differed significantly between the tamsulosin and other a1-ARA groups and the no
a1-ARA group (P<.0005 and PZ.017, respectively) and between the tamsulosin group and the
other a1-ARA group (PZ.027). On regression analysis, the hazard ratio for overall IFIS
incidence was 3.8 in the other a1-ARA group (PZ.012) and 10.1 in the tamsulosin group
(P<.0005). Pupil size was inversely related to IFIS incidence and severity (P<.0005). A dilated
pupil of 7.0 mm or smaller had 73% sensitivity and 95% specificity for predicting IFIS (PZ.0001).
CONCLUSIONS: Pupil dilation was inhibited by a1-ARAs, in particular tamsulosin. For a pupil
7.0 mm or smaller, the risk for IFIS existed regardless of a1-ARAs treatment, which surgeons
should take into consideration.
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J Cataract Refract Surg 2011; 37:1447–1454 Q 2011 ASCRS and ESCRSIntraoperative floppy-iris syndrome (IFIS) was first
described by Chang and Campbell in 20051 when pa-
tients using systemic a1-adrenergic receptor antago-
nists (a1-ARAs) were noted to have an increased risk
for iris complications during phacoemulsification.
The clinical definition of this small-pupil syndrome
is a triad of intraoperative observations, including
floppy iris stroma that surges and billows to normal
intraoperative fluidics, prolapse of iris stroma through
surgical incisions despite well-constructed wounds,
and progressive intraoperative miosis with standard
preoperative dilation.1,2 Two additional characteristics
often accompany IFIS; that is, poor preoperative pupil
dilation and reduced motility of the pupil margin. Thed ESCRS
ier Inc.extent of the syndrome’s clinical presentation
varies widely, ranging from mild, with a fluttering
iris only, tomore severe cases that feature the complete
triad of signs.3 The latter involves a high rate of intra-
operative complications, such as iris trauma, zonular
dehiscence, posterior capsule rupture, and vitreous
loss, as well as postoperative complications, including
intraocular pressure (IOP) elevation and cystoid mac-
ular edema (CME).1,2,4
A poorly dilating pupil is not an uncommon finding
during cataract surgery and may have various causes,
including glaucoma, diabetes, and pseudoexfoliation,
while iris prolapse into the phaco tunnel can be caused
by elevated IOP.5 However, in IFIS patients, the0886-3350/$ - see front matter 1447
doi:10.1016/j.jcrs.2011.02.030
1448 PHARMACOLOGIC PUPIL DILATION AS A PREDICTOR OF IFISclinical characteristics of the iris during cataract sur-
gery typically differ, mainly due to the hypotonically
fluttering iris during irrigation/aspiration (I/A).5
Systemic a1-ARAs have become accepted as first-
line therapy for benign prostatic hyperplasia (BPH)
and lower urinary tract symptoms,6,7 which are prev-
alent in the elderly male population. Because of their
nonselectivity, the a1-ARAs alfuzosin, doxazosin,
and terazosin also inhibit vasculature smooth-muscle
contraction, leading to an increased incidence of ortho-
static hypotension.8 Tamsulosin, in comparison, has
up to 20 times the affinity for the a1-A receptor
subtype1,8–10 and improves urinary outflow with min-
imum effect on vasculature smoothmuscles. Although
IFIS may have a multifactor etiology, systemic treat-
ment with an a1-ARA seems to play a pivotal
role.11,12 The association between tamsulosin and
IFIS has been confirmed in numerous studies,5,13–15
as has the fact that IFIS may occur in patients taking
other a1-ARAs.11,13,16–20 In the 2008 American Society
of Cataract and Refractive Surgery (ASCRS) IFIS sur-
vey,21 95% of experienced surgeons reported that sys-
temic treatment with the a1-ARA tamsulosin makes
cataract surgery more difficult and leads to higher
rates of complications. Therefore, it would be helpful
to predict preoperatively which patients are at risk.3,8
Rather than regarding IFIS as a rare, unexpected,
and unpredictable syndrome attributed to 1 drug,
IFIS predisposition should be predictable via careful
evaluation of pupil size behavior. A recent study by
Chen et al.22 found that a preoperative dilated pupil
diameter smaller than 6.5mmwas significantly associ-
atedwith an increased incidence of IFIS in patients tak-
ing tamsulosin.
This prospective cohort study attempted to predict
IFIS risk and severity by pupil size in male patients
having cataract surgery. It assessed the influence of
various a1-ARAs on pupil diameter under mesopic
conditions and after pharmacologic dilation. It then
analyzed the predictive power of these parameters
with respect to IFIS onset.Submitted: January 12, 2011.
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J CATARACT REFRACT SURG -PATIENTS AND METHODS
Consecutive male cataract patients having phacoemulsifica-
tion at the Ophthalmology Section, University of Palermo,
Italy, from June to December 2009 were prospectively re-
cruited. The study adhered to the tenets of the Declaration
of Helsinki, and the research protocol received institutional
review board approval. Patients were thoroughly informed
about the procedures and provided written consent.
Three groups were evaluated: patients taking tamsulosin
for at least 1 year, patients taking another a1-ARA for at
least 1 year, and control patients taking no a1-ARA. The in-
clusion criterion for the no a1-ARA controls was age match.
The exclusion criteria were diabetes, glaucoma, pseudoex-
foliation syndrome, previous ocular trauma, use of eye-
drops other than artificial tears, a history of iridocyclitis,
iris neovascularization, previous eye surgery, traumatic cat-
aract, zonular dialysis, and inability to give informed con-
sent. Medication histories for all patients were recorded.
The data-collection team was masked to patient-group
affiliation.Pupil MeasurementOne month before surgery, 2 pupil measurements were
taken using a computerized infrared pupillometer (Sirius,
Costruzione Strumenti Oftalmici) under mesopic low (0.4
lux) and mesopic high (4.0 lux) illumination. The pupil was
then dilated with 2 drops of tropicamide 0.5%–phenyleph-
rine hydrochloride 10% (Visumidriatic Fenilefrina), and 20
minutes later a third measurement was taken under mesopic
high (4.0 lux) conditions.
Approximately 15 to 20 minutes before scheduled sur-
gery, mydriasis was obtained by instillation of 2 drops of tro-
picamide 0.5%–phenylephrine hydrochloride 10%, repeated
once after 5 to 10 minutes. This was followed after an addi-
tional 10 minutes by 3 drops of lidocaine hydrochloride 4%
(Alfa Intes). No topical atropine or cyclopentolate was
used before surgery. The surgeon performed the fourth
and fifth measurements using calipers immediately before
and at the conclusion of surgery.Surgical TechniqueThe same experienced surgeon (S.C.) performed all sur-
geries. A temporal 2.75 mm near-clear corneal tunnel inci-
sion was created with a precalibrated knife (Becton
Dickinson). A 1.1 mm (19-gauge) side-port precalibrated
knife (Alcon Laboratories, Inc.) was used to create a superior
limbal incision 60 to 90 degrees from the former. No direct
intracameral injection of epinephrine or phenylephrine was
used. A capsulorhexis was created with a forceps after visco-
mydriasis was obtained, if necessary, using a dispersive or
viscoadaptive high-viscosity ophthalmic viscosurgical de-
vice (OVD) (sodium hyaluronate 3.0%–chondroitin sulfate
4.0% [Viscoat] or sodium hyaluronate 2.3% [Healon5]). The
irrigation fluid consisted of a balanced salt solution with
1:1 000 000 adrenaline. Disposable iris retractors were ap-
plied when significant miosis or billowing followed OVD
progressive evacuation with the phaco handpiece. Phaco-
emulsification was performed with the Sovereign Whitestar
machine (Abbott Medical Optics, Inc.) using a 19-gauge pha-
co tip. Intraocular lens (IOL) implantation was performed
through an Unfolder Emerald or Silver injector system (Ab-
bott Medical Optics, Inc.) or through aMonarch II IOLDeliv-
ery System (Alcon Italia SpA) without enlarging the tunnelVOL 37, AUGUST 2011
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tion. All patients received topical ofloxacin (Exocin) for 3
days preoperatively and tobramycin–dexamethasone oph-
thalmic suspension (Tobradex) for 4 weeks postoperatively.Intraoperative Floppy-Iris Syndrome Grading
and ComplicationsThe severity of IFIS was assessed during OVD phaco aspi-
ration, after removal of iris retractors, and during OVD aspi-
ration with the I/A handpiece. Based on Chang et al.,3
intraoperative iris behavior was graded as follows: no IFIS
(stable normal iris with no significant miosis), mild IFIS
(slightly noticeable floppy iris, minor or no miosis, and no
tendency of iris prolapse), moderate IFIS (floppy iris, signif-
icant miosis and small tendency toward iris prolapse), and
severe IFIS (floppy iris, significant miosis, and strong ten-
dency toward iris prolapse). Significant miosis was defined
as a 3.0mm ormore decrease in pupil diameter if mechanical
iris devices were used or a 2.0 mm or more decrease in pupil
diameter if no iris devices were used. The surgeon was
masked to patient drug history and mydriatic pupil size at
the first examination. The occurrence of any sign of IFIS
was recorded immediately after surgery.
Intraoperative complications, including posterior capsule
rupture, vitreous loss, iris prolapse, iris tears, iris catching by
phaco or I/A tip, iridodialysis, and hyphema, were recorded
immediately after surgery. Postoperative complications,
such as persistent uveitis, persistent IOP rise, and clinical
CME, and iris abnormalities, such as pupil distortion, poste-
rior synechiae, iridodialysis, iris stromal tears, transillumina-
tion defects, and permanent mydriasis, were also noted.Power Calculation and Statistical AnalysisBased on a power calculation, a sample size of 50 patients
per group was determined to allow detection of a minimum
clinically relevant difference in pupil diameter of 0.5 mm,
with a standard deviation (SD) of 0.6. The sample size took
into account a significance level of 5% and a power of 80%
for a 2-sided test.
Statistical analysis was performed using Epi Info software
(version 3.2.2, U.S. Center for Disease Control and Preven-
tion) and SPSS software (version 14.0, SPSS, Inc.). The results
are expressed as the mean G SD. Univariate analysis ofTable 1. Patient characteristics and pupil size measurements under mes
group.
Parameter
Mean
Tamsulosin Group Other a1-A
Age (y) 75.2G 6.2 72.5G
Pupil size (mm)
Mesopic low 3.8G 1.1 4.0G
Mesopic high 2.8G 0.3 2.9G
1 mo preop 7.1G 1.3 7.6G
Preop 7.3G 0.4 7.7G
Postop 6.2G 1.6 6.4G
a1-ARAZ a1-adrenergic receptor antagonist
*Univariate analysis of variance
J CATARACT REFRACT SURG -variance (ANOVA)was used to compare pupil diameters be-
tween the groups and post hoc analysis with the Bonferroni
test to determine whether there were pairwise differences.
Categorical variables were compared using the chi-square
test with Yates correction, as needed. Logistic regression
analysis was used to evaluate hazard ratios with 95% confi-
dence intervals (CIs) for IFIS incidence. To assess the predic-
tive rate of different cutoff values of pupil size diameter,
a receiver operating characteristic (ROC) curve with calcula-
tions of area under the curve and 95% CIs was constructed
and sensitivity, specificity, and accuracy were calculated.
All P values were 2-sided, and P values less than 0.05 were
considered to indicate statistical significance.
RESULTS
The study enrolled 150 patients, 50 in each of the 3
groups. In the other a1-ARA group, 15 patients were
taking alfuzosin, 15 patients were taking terazosin,
and 20 patients were taking doxazosin. Table 1 shows
the patient characteristics and pupil size measure-
ments under mesopic low and high conditions and af-
ter pharmacologic dilation by group. There was no
statistically significant difference in mean age or pupil
diameter under mesopic low and mesopic high condi-
tions between the 3 groups. One month before sur-
gery, there was a significant difference between all
groups in pupil size after dilation (PZ.001, univariate
ANOVA test). Mydriasis was less in the tamsulosin
group than in the other a1-ARA group and the no
a1-ARA group (PZ.033 and PZ.0003, respectively,
Bonferroni post hoc test). Mydriasis was also less in
the other a1-ARA group than in the no a1-ARA group
(PZ.001, Bonferroni post hoc test). Immediately be-
fore surgery, mydriasis differed significantly between
all groups (P!.0005, univariate ANOVA test). Mydri-
asis was less in the tamsulosin group than in the other
a1-ARA group and the no a1-ARA group (PZ.0002
and P!.0001, Bonferroni post hoc test). Mydriasis in
the other a1-ARA group was less than in the no
a1-ARA group (P!.0001, Bonferroni post hoc test).opic low and high conditions and after pharmacologic dilation by
G SD
P Value*RA Group No a1-ARA Group
5.6 73.8G 10.5 .238
0.7 4.0G 0.9 .326
0.5 3.0G 0.6 .065
1.0 7.9G 0.8 .001
0.6 8.2G 0.2 !.0005
1.6 7.7G 0.3 !.0005
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Table 2. Frequency of IFIS incidence by group and IFIS grade (P!.0005).*
IFIS Grade
Incidence, n (%)
TotalTamsulosin Group Other a1-ARA Group No a1-ARA Group
None 21 (42) 33 (66) 44 (88) 98 (65)
Mild 12 (24) 3 (6) 5 (10) 20 (13)
Moderate 13 (26) 14 (28) 1 (2) 28 (19)
Severe 4 (8) 0 0 4 (3)
a1-ARAZ a1-adrenergic receptor antagonist; IFISZ intraoperative floppy-iris syndrome
*Chi-square test with Yates correction
1450 PHARMACOLOGIC PUPIL DILATION AS A PREDICTOR OF IFISPostoperatively, there were significant differences in
pupil size between the 3 groups (P!.0005, univariate
ANOVA test); the pupil size was smaller in the tamsu-
losin group and the other a1-ARA group than in the no
a1-ARA group (P!.0005, Bonferroni post hoc test). No
difference was found between the tamsulosin group
and the other a1-ARA group.
There were a total of 52 cases of IFIS, 29 (58%) in the
tamsulosin group, 17 (34%) in the other a1-ARA
group, and 6 (12%) in the no a1-ARA group. Table 2
shows the frequency of IFIS by group and IFIS grade;
the frequency differed significantly between all the
groups (P!.0005, Pearson c2 test). The incidence of
overall IFIS (Table 3) differed significantly between
the tamsulosin group and the no a1-ARA group
(P!.0005, Yates corrected chi square), between the
other a1-ARA group and the no a1-ARA group
(PZ.017, Yates corrected c2), and between the tamsu-
losin group and the other a1-ARA group (PZ.027;
Yates corrected c2) (Table 3). Further, regression anal-
ysis found a hazard ratio for IFIS of 10.1 (95% CI,
3.6-28.1; P!.0005) for tamsulosin and a hazard ratio
of 3.8 (95% CI, 1.3-10.6; PZ.012) for other a1-ARAs.
No statistically significant differences were found in
pupil size, any condition, or the occurrence of IFISTable 3. Frequency of overall IFIS incidence by group
(PZ!.0005).
Group
Frequency, n (%)
P Value*No IFIS
Overall IFIS (Mild,
Moderate, Severe)
No a1-ARA 44 (88) 6 (12) d
Other a1-ARA 33 (66) 17 (34) .017†
Tamsulosin 21 (42) 29 (58) !.0005†
.027z
a1-ARA Z a1-adrenergic receptor antagonist; IFIS Z intraoperative
floppy-iris syndrome
*Chi-square test with Yates correction
†Versus no a1ARA group
zVersus other a1ARA group
J CATARACT REFRACT SURG -between the other a1-ARA subgroups (ie, alfuzosin,
terazosin, and doxazosin).
Pupil size after pharmacologic dilation 1 month be-
fore surgery, after preoperative dilation, and postoper-
atively correlated with the incidence of IFIS (P!.0005,
univariate ANOVA test) (Table 4). Post hoc analysis
indicated that pupil size was inversely related to over-
all IFIS incidence and to IFIS severity (Table 4). The
ROC curve analysis using the dilated pupil measure-
ment showed that a pupil 7.0 mm or smaller predicted
IFIS with 73% sensitivity (95% CI, 70%-84%) and 95%
specificity (95% CI, 89%-98%) (PZ.0001) (Figure 1).
The ROC curve subanalysis for IFIS severity indicated
that a dilated pupil smaller than 7.0 mm was predic-
tive of moderate IFIS (sensitivity 86%: 95% CI, 70%-
96; PZ.0001) (specificity 90%: 95% CI, 83%-95%;
PZ.0001) and severe IFIS (sensitivity 96%: 95% CI,
75%-98%; PZ.0001) (specificity 90%: 95% CI,
75%-96%; PZ.0001) but not of mild IFIS. The overall
diagnostic accuracy of IFIS prediction by pupil size
evaluation using the 7.0 mm threshold was 85%.
Few intraoperative complications occurred. Dispos-
able iris retractors were used in 10 patients (20%) in the
tamsulosin group, 7 patients (14%) in the other a1-
ARA group, and 1 patient (2%) in the no a1-ARA
group. Momentary aspiration of the iris with the pha-
co tip was uncommon because of prompt application
of iris retractors. Focal iris stromal atrophy caused by
retractors or prolapse was a common occurrence. No
patient had an irregular or permanently dilated pupil
as a result of surgical iris sphincter trauma. Three pa-
tients had a capsulorhexis tear during phacoemulsifi-
cation; however, the IOL was successfully implanted
in the capsular bag in all cases. There were no cases
of intraocular hemorrhage, posterior capsule rupture,
or vitreous loss. On the first postoperative day, 28
eyes (18.6%) had a transient IOP elevation over
22 mm Hg; no patient had protracted IOP elevation.
In the early postoperative period, clinical CME was
present in 3 cases (2%). The corrected distance visual
acuity was 20/40 or better in all eyes at the 1-month
follow-up visit.VOL 37, AUGUST 2011
Table 4. Relationship between pupil-size measurements after dilation and IFIS grade.
Exam
IFIS Grade P Value*
No IFIS
Mild
IFIS
Moderate
IFIS
Severe
IFIS Overall
No Vs
Mild
No Vs
Moderate
No Vs
Severe
Mild Vs
Moderate
Mild Vs
Severe
Moderate Vs
Severe
1 mo
preop
7.8G 0.9 7.1G 0.7 7.1G 1.4 5.2G 0.2 !.0005 .024 .006 .0005 d .002 .001
Preop 7.7G 0.3 7.2G 0.6 6.9G 0.4 6.5G 0.2 !.0005 !.0005 !.0005 !.0005 .016 .004 d
Postop 7.5G 0.7 5.9G 1.3 5.2G 1.0 3.0G 0.3 !.0005 !.0005 !.0005 !.0005 .05 !.0005 !.0005
IFISZ intraoperative floppy-iris syndrome
*Univariate analysis of variance and post hoc analysis with Bonferroni test
1451PHARMACOLOGIC PUPIL DILATION AS A PREDICTOR OF IFISDISCUSSION
Cataract extraction is one of the most frequently per-
formed surgeries in developed countries.23 Adequate
pupil dilation and subsequent stability of the iris dur-
ing surgery are key to successful and safe
phacoemulsification.24
As stated, IFIS can increase the risk for intraopera-
tive complications if not identified and managed early
in otherwise uncomplicated cataract surgery.1,3,4 The
importance of predicting IFIS before phacoemulsifica-
tion becomes evidentwhen reviewing surgical compli-
cations in the peer-reviewed literature. Early
retrospective studies of IFIS showed posterior capsule
rupture rates of 7%13 to 12%.1 Prospective data col-
lected by Chang and Campbell1 and Chang et al.3 afterFigure 1. The ROC curve for determination of predictive value of
pupil size measurement after dilation for IFIS incidence (area under
the curveZ 0.859).
J CATARACT REFRACT SURG -the characteristics of IFIS had been well defined and
management techniques had been explored showed
a reduction in the posterior capsule rupture rate to
zero. From these studies, it is evident that an under-
standing of this important clinical syndrome makes
a significant difference in whether IFIS will lead to in-
traoperative complications. This also points to the
need to identify all risk factors involved in IFIS.8,12
In high-volume cataract surgery units, especially
those with less experienced surgeons, IFIS prediction
and recognition are especially important. In a study
of cataract extractions performed by resident physi-
cians, the reported incidence of posterior capsule rup-
ture and vitreous loss was 7.4% in patients taking
tamsulosin compared with 1.8% in patients not taking
tamsulosin.22 Even for experienced surgeons, the rate
of vitreous loss during cataract surgery in patients tak-
ing tamsulosin ranges from 0.6% for high-volume sur-
geons to 7.0% and 12.0% in United States and United
Kingdom surveys, respectively.1,13,21,22 However,
when IFIS is anticipated and proper management
strategies are used, the outcome is favorable and the
complication rate is low for both skilled surgeons
and residents.3,22,25
The present study found no difference in pupil di-
ameter under mesopic conditions between patients
on tamsulosin, patients on another a1-ARA, or pa-
tients on no a1-ARA. This may be due to the complex-
ity of the biology of the aging iris in which multiple
factors affect pupil functionality and could overcome
the a1-ARA effect. For instance, the pupil decreases
in size with advanced age, independent of a mydriatic
effect.11,26 In general, medical conditions associated
with endothelial dysregulation (eg, congestive heart
failure, diabetes, hypertension) have the potential to
affect iris integrity.11
However, the pharmacologic induction of mydria-
sis in this study was adequate to show the effect of
a1-ARAs, in particular tamsulosin, on iris smooth
musculature, with a reduction in the mydriaticVOL 37, AUGUST 2011
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tients not on a1-ARAs. Thiswas truewith the standard
protocol for mydriasis induction and with the heavier
preoperative instillation of mydriatics plus topical li-
docaine, whose mydriatic effect is known.27 At the
end of surgery, patients taking a1-ARAs had clearly
reduced pupil diameters comparedwith those not tak-
ing a1-ARAs. A difference between tamsulosin and
other a1-ARAs was not found; however, the higher
rates of surgical trauma and use of mechanical iris
retractors in these groups could have masked
a difference.
The overwhelmingmajority of IFIS cases in the pres-
ent study were in patients on a1-ARA treatment, with
severe cases found only in the tamsulosin group (8% of
the group). Our results agree with those in the litera-
ture, in which the reported incidence of IFIS ranges
from 43% to 100% in patients treated with tamsulo-
sin.1,2,4,15,28 The greater incidence and severity of IFIS
in our tamsulosin group than in the other a1-ARA
group is supported by the findings in the ASCRS sur-
vey21 and is in agreement with the hypothesis that the
systemic use of less selective a1A-subtype antagonists
leads to a lower prevalence of IFIS.1,15,28,29 A recent
study from Canada4 reports an adjusted odds ratio
of 32 for IFIS in patients exposed to tamsulosin com-
pared with those exposed to alfuzosin. Another study
based on an animal model found that the plasma con-
centration of tamsulosin antagonized pupil dilation,
whereas that of alfuzosin did not.25
Chang et al.3 and Chang30 found that IFIS was less
common and less severe in patients taking nonselec-
tive a blockers, such as alfuzosin, doxazosin, and tera-
zosin. It is not clear why nonselective a1-ARAs inhibit
pharmacologic mydriasis in humans but are not
strongly associatedwith IFIS. However, prostate bind-
ing studies clearly show that these drugs have differ-
ent receptor-affinity profiles than tamsulosin.6,31
The mainly mild IFIS in 12% of patients in our no
a1-ARA group is not surprising when data in the liter-
ature are analyzed. For example, 36% of respondents
in the ASCRS survey noted IFIS with drugs other
than a1-ARAs.21 Drugs that have been associated
with IFIS include saw palmetto, an herbal supplement
used for BPH; finasteride; antipsychotic drugs; and
some b-blockers with particular a-blocking proper-
ties.12,21,32–35 Other drugs that might induce iris dilator
smooth-muscle relaxation include endothelin-A
antagonists, angiotensin antagonists, and nitric oxide
donor compounds.8,11
Certain systemic diseases, such as diabetes, hyper-
tension, and congestive heart failure, can affect intra-
operative iris behavior.11,12 Schwinn and Afshari11
hypothesize that because of the complexity of signal-
ing pathways in the iris, a1-ARAs are merely theJ CATARACT REFRACT SURG -beginning of our understanding of IFIS and that a con-
stellation of factors more complex than previously
thought affects the causes of IFIS.
Our results on the pupillary mydriatic response
with IFIS incidence and severity in various patient
groups are dependent on the mydriatic regimen cho-
sen and irrigation with balanced salt solution contain-
ing adrenaline. Alternative management strategies,
such as preoperative topical nonsteroidal antiinflam-
matory drugs, cyclopentolate, atropine, intracameral
epinephrine, or pupil expansion rings, could yield dif-
ferent results. These factors, together with the sur-
geon’s subjective perception of the degree of severity
of IFIS, especially in mild cases, may help explain the
widely variable incidences and severity of IFIS re-
ported in the literature.3,21,22
With respect to IFIS prediction by pharmacologi-
cally dilated pupil size, such a possibility seems viable
on the basis of our results. In general, preoperative and
postoperative measurements taken with computer-
ized pupillometer or calipers appear to be inversely re-
lated to the incidence and severity of IFIS. The results
in this prospective study agree with the retrospective
data from Chen et al.22 in patients taking tamsulosin,
which showed that the incidence of IFIS, regardless
of severity, was higher in eyes with smaller preopera-
tive dilated pupils. The high sensitivity (73%) and
specificity (95%) in our ROC curve analysis confirm
the value of the 7.0mmdilated pupil threshold in iden-
tifying patients at risk for moderate or severe IFIS. Our
ROC curve analysis results indicate that with a pupil
diameter of 7.0 mm or less, not only patients taking
a1-ARAs but even those not taking a1-ARAs are at
risk for IFIS, with high diagnostic accuracy. The degree
of the risk in a patient not taking a1-ARAs is probably
bound to the complex constellation of factors de-
scribed above. For instance, the incorporation of saw
palmetto into multivitamin formulations is becoming
common, and the widespread use of multivitamins
makes it difficult to quantify the actual incidence of
saw palmetto use by the general population. It is there-
fore conceivable that undocumented use of saw pal-
metto could be the cause in IFIS cases with no clearly
associated factors.8,12 Moreover, the possibility cannot
be excluded that the patients who had IFIS in the con-
trol group could have been exposed to tamsulosin in
the past but they had no accurate memory to report
to the investigators. The rate of complications in this
study was within the limits previously reported for
high-volume experienced surgeons and similar to the
reported rate after standard phacoemulsification
with IOL implantation.3,22,36,37
This study had several limitations, including the
small number of events per variable. Peduzzi et al.38
recommend a model that include a minimum of 10VOL 37, AUGUST 2011
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size calculations were performed and their require-
ments exceeded, this study would have benefited
from a larger sample. Because of the limited sample
size, we cannot draw firm conclusions about the inci-
dence of IFIS in the subgroups of patients taking differ-
ent nonselective a1A-subtype antagonists; therefore,
our data are not suitable to differentiate the effect of al-
fuzosin, terazosin, and doxazosin. Also, given the na-
ture of IFIS as an intraoperative surgical phenomenon,
this study relied on the surgeon’s subjective assess-
ment of IFIS, which could have been influenced by
the immediate preoperative pupil size.
In conclusion, this study confirmed inhibition of pu-
pil pharmacologic dilation by various a1-ARAs, in par-
ticular tamsulosin. The ROC curves indicate that
dilated pupil size can predict IFIS risk and severity.
Therefore, careful dilated-pupil measurements should
become part of preoperative protocol in preparation
for surgery. A dilated pupil of 7.0 mm or smaller in
a patient not affected by diabetes, glaucoma, or pseu-
doexfoliation increases the risk for IFIS, even without
a clear history of a1-ARA administration. In such
cases, the surgeon should supplement the informed
consent process and consider perioperative strategies
(atropine eyedrops, epinephrine for intracameral injec-
tion or in the irrigation solution, viscoadaptive or
a soft-shell technique, iris retractors or pupil expansion
rings). Furthermore, patients using an a1-ARA should
be operated on by experienced surgeons who have the
judgment on whether to make relevant changes in the
procedure and on managing preoperative or intrao-
perative preventive strategies.8,39 In countries with
large elderly populations, it is important to pursue
identification of other factors, by further studies, that
put patients at risk for IFIS.
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